Share This Article:

Autoantibodies to GFAP (glial fibrillary acidic protein) and to dopamine in patients with acute and chronic cerebrovascular disоrders

Abstract Full-Text HTML Download Download as PDF (Size:191KB) PP. 1366-1371
DOI: 10.4236/health.2010.212202    3,211 Downloads   6,649 Views   Citations


We have studied the level of autoantibodies to neurospecific proteins and neurotransmitters in patients with different forms of ischemic brain lesion. 49 patients with acute (ishemic stroke) and chronic cerebrovascular disease, 14 patients with ishemic heart disease and control group (35 healthy subjects) were investigated. The serum level of autoantibodies to glial fibrillary acidic protein (GFAP) and to dopamine (D) was determinated by ELISA. The content of autoantibodies to GFAP and D in patients with ischemic heart disease was practically identical. The patients with acute and chronic cerebrovas-cular diseases had the significally increased level of autoantibodies. The level of autoantibodies to GFAP in patients with acute vascular accidents (ischemic stroke) with favorable outcome was significantly higher than in patients with chronic cerebral ischemia. The obtained data allowed us to consider serum level of autoantibodies to GFAP as a marker of ischemic brain lesion, and to suppose further potential role of this autoantibodies in cerebrovascular disease progression.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Kamchatnov, P. , Chugunov, A. , Ruleva, N. , Dugin, S. , Basse, D. , Abusueva, B. , Buriachkovskaya, L. and Gusev, E. (2010) Autoantibodies to GFAP (glial fibrillary acidic protein) and to dopamine in patients with acute and chronic cerebrovascular disоrders. Health, 2, 1366-1371. doi: 10.4236/health.2010.212202.


[1] Gusev, E.I. and Skvortsova, V.I. (2003) Brain ischemia. Kluwer Academic Publishers, New York.
[2] Anand, N. and Stead, L. (2005) Neuron-specific enolase as a marker for acute ischemic stroke: A systematic review. Cere-Brovascular Diseases, 20, 213-219.
[3] Foerch, C., Singer, O., Neumann-Haefelin, T., et al. (2005) Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Archives of Neurology, 62, 1130-1134.
[4] Foerch, C., Curdt, I., Yan, B., et al. (2006) Serum glial fibrillary acidic protein as a biomarker for intracerebral haemor-rhage in patients with acute stroke. Journal of Neurology, Neurosurgery, and Psychiatry, 77,181-184.
[5] Herrmann, M., Vos, P., Wunderlich, M., et al. (2000) Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke, 31, 2670-2677.
[6] Korzhevskii, D.E., Otellin, V.A. and Grigor’ev, I.P. (2005) Glial fibrillary acidic protein in astrocytes in the human neocortex. Neuroscience and Behavioral Physiology, 35, 789-792.
[7] Schroeter, M., Schiene, K., Kraemer, M., et al. (1995) Astroglial responses in photochemically induced focal ischemia of the rat cortex. Experimental Brain Research, 106, 1-6.
[8] Aldskogius, H. and Kozlova, E. (1998) Central neu-ron-glial and glial-glial interactions following axon injury. Progress in Neurobiology, 55, 1-26.
[9] Kato, H., Kogure, K., Araki T. and Itoyama, Y. (1994) Astroglial and microglial reactions in the gerbil hippo-campus with induced ischemic tolerance. Brain Research, 664, 69-76.
[10] Wilhelmsson, U., Li, L., Pekna, M., et al. (2004) Absence of glial fibrillary acidic protein and vimentin prevents hy-per-trophy of astrocytic processes and improves post- traumatic regeneration. Journal of Neuroscience, 24, 5016- 5021.
[11] Si, X., Miguel-Hidalgo, J., O’Dwyer, G., et al. (2004) Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology, 29, 2088-2096.
[12] Webster, M., Knable, M., Johnston-Wilson, N., et al. (2001) Immunohistochemical localization of phosphory-lated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bi-polar disorder, and depression. Brain, Behavior, and Im-munity, 15, 388-400.
[13] Poletaev, A.B., Morozov, S.G., Gnedenko, B.B., et al. (2000) Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental neurological disorders.Autoimmunity, 32, 33-38.
[14] Sanna, G., Piga, M., Terryberry, J.W., et al. (2000) Central nervous system involvement in systemic lupus ery-thematosus: Cerebral imaging and serological profile in patients with and without overt neuropsychiatric manife-stations. Lupus, 9, 573-583.
[15] Terryberry, J.W., Thor, G. and Peter, J.B. (1998) Autoan-tibodies in neurodegenerative diseases: Antigen-specific frequencies and intrathecal analysis. Neurology of Aging, 19, 205-216.
[16] Melehov, M.G., Ruleva, N.Yu., Lyucova, T.K. and Dugin, S.F. (2004) Potentiating effect of nicotine on inflammation and induction of autoantibodies in rats. Russian Physiological Journal named after Sechenov, 90, 638- 644.
[17] Stein, T.D., Fedynyshyn, J.P. and Kalil, R.E. (2002) Cir-culating autoantibodies recognize and bind dying neurons following injury to the brain. J. Neuropathol. Exp. Neurol, 61, 1100-1108.
[18] Poletaev, A.B., Alferova, V.V., Abrosimova, A.A., et al. (2003) Natural neurotropic antibodies and nervous system pathology. Neuroimmunology, 1, 11-17.
[19] Ruleva, N.Yu., Kuzin, V.M., Kamchatnov, P.R., et al. (2004) Markers of inflammation, autoantibodies to neu-rospecific antigens and outcome in patients with acute ischemic stroke. Journal of Neurology and Psychiatrics, 12, 43-47.
[20] Magri, G., Clerici, M., Dall’Ara, P., et al. (2005) Decrease in pathology and progression of scrapie after im-munisation with synthetic prion protein peptides in ham-sters. Vaccine, 23, 2862-2868.
[21] Ishida, K., Kaneko, K., Kubota, T., et al. (1997) Identifi-cation and characterization of an anti-glial fibrillary acidic protein antibody with a unique specificity in a demented patient with an autoimmune disorder. Journal of the Neurological Sciences, 151, 41-48.
[22] Mecocci, P., Parnetti, L., Donato, R., et al. (1992) Serum autoan-tibodies against glial fibrillary acidic protein in brain aging and senile dementias. Brain, Behavior, and Immunity, 6, 286-292.
[23] Bornstein, N., Aronovich, B., Korczyn, A., et al. (2001) Antibodies to brain antigens following stroke. Neurology, 56, 529-530.
[24] Moalem, G., Leibowitz-Ami, R., Yoles, E., et al. (1999) Autoimmune T cells protect neurons from secondary de-generation after central nervous system axotomy. Nature Medicine, 5, 49-55.
[25] Dambinova, S., Khounteev, G., Izykenova, G., et al. (2003) Blood test detecting autoantibodies to N-methyl- D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clinical Chemistry, 49, 1752-1762.
[26] Mor, F. and Cohen, I. (2006) How special is a pathogenic CNS autoantigen? Immunization to many CNS self-antigens does not induce autoimmune disease. Journal of Neuro-immunology, 174, 3-11.
[27] Ruleva, N.Yu., Dugin, S.F., Kamchatnov, P.R., Lyukova, T.K., Chugunov, A.V., Martynov, M.Yu and Gusev, E.I. (2005) Autoantibodies to dopamine and outcome after acute ischemic stroke. Neuroimmunologia, 3, 22-25.
[28] Becker, K., Kindrick, D., Lester, M., et al. (2005) Sensi-tization to brain antigens after stroke is augmented by li-popolysac-charide. Journal of Cerebral Blood Flow & Metabolism, 25, 1634-1644.
[29] Schenk, D., Barbour, R., Dunn, W., et al. (1999) Immu-nization with amyloid-beta attenuates Alzheimer- dis-ease-like pathology in the PDAPP mouse. Nature, 400, 173-177.
[30] Zimmer, D.B., Chaplin, J., Baldwin, A. and Rast, M. (2005) S100-mediated signal transduction in the nervous system and neurological diseases. Cell and Molecular Biology, 51, 201-214.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.